CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$2.90
-0.09 (-3.01%)
▼
5d:
-11.85%
30d:
-8.81%
90d:
-19.22%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 03, 2026
19d
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLLS is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLLS is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $2.90, which is considered slightly low relative to its 30-day fair value range of $2.89 to $3.16.
Technical Outlook: Technically, CLLS is in a downtrend. Immediate support is located at $2.70, while resistance sits at $3.39. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+162.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLLS is in a downtrend. Immediate support is located at $2.70, while resistance sits at $3.39. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+162.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.89 -
$3.16
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 162.1% below Wall St target ($7.60)
- WARNING: Recommendation downgraded due to -11.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.89 -
$3.16
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.70
Resistance Level
$3.39
Current Trend
Downtrend
Technical data as of
Jul 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.28
Wall Street Target
$7.60
(+162.1%)
Revenue Growth (YoY)
-37.3%
Profit Margin
-89.5%
Share & Embed Analysis
Last updated: July 14, 2026 2:08 AM ET
Data refreshes hourly during market hours. Next update: 3:08 AM
Data refreshes hourly during market hours. Next update: 3:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
